Medication info
Schvastin Tablets 10mg (Rosuvastatin Calcium)

Schvastin Tablets 10mg (Rosuvastatin Calcium)

Prescription medicationTablet
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Vivozon Pharmaceutical Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
100 tablets/box [10 tablets/Alu-Alu×10], 30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201504202 · Approved 2015.06.29 · Insurance code 658202850

Summary

Main use
Improvement of dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.
Children's dosage
Ages 10 years ~ 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Vivozon Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunctive treatment in patients with primary hypercholesterolemia and mixed dyslipidemia when dietary changes and exercise alone are not sufficient. It is also effective as an adjunct to diet for patients with homozygous familial hypercholesterolemia or primary dysbetalipoproteinemia. This drug lowers total cholesterol and LDL-cholesterol levels in patients with hypercholesterolemia, delaying the progression of atherosclerosis, and is considered safe for pediatric patients between the ages of 10 and 17 with familial hypercholesterolemia. In middle-aged and older patients at high risk for cardiovascular disease, it helps to reduce the risks of stroke, myocardial infarction, and vascular revascularization procedures. Overall, this medication is used to improve blood lipid levels and reduce the risk of cardiovascular disease.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is needed. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased to a maximum of 20 milligrams per day. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients.

Children's dosage

Ages 10 years ~ 17 years: The usual dose range is 5 milligrams ~ 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be taken by individuals who are allergic to any of its components. Persons with severely impaired liver function or liver disease should also avoid using this medication. Individuals with muscle-related diseases or a history of muscle problems should not take this drug. Caution should be exercised when taken with certain immunosuppressants as it may pose risks. Patients with severely impaired kidney function should avoid this medication. Pregnant or nursing women, as well as women of childbearing potential, should consult a doctor before taking this medication. The 40mg dose is contraindicated for individuals at high risk for muscle disease. People with lactose intolerance or certain genetic metabolic disorders should not take this drug. Individuals who consume large amounts of alcohol or have a history of liver disease should undergo liver function tests before starting this medication and receive regular monitoring during treatment. If symptoms of myalgia or muscular weakness occur, inform healthcare professionals immediately, and in severe cases, the medication may need to be discontinued. Careful monitoring is required for patients at high risk for muscle disease when taking this drug. Patients with hypothyroidism or nephrotic syndrome should treat the respective conditions before administering this medication. Severe myasthenia gravis or ocular myasthenia may occur, and if these symptoms arise, the medication should be stopped. This drug may interact with other medications, which may necessitate dosage adjustments or contraindications depending on the drugs taken concurrently. Particularly, when used in conjunction with fibrate medications, the risk of myopathy increases, so caution is warranted. Regular kidney function tests may be required for those on high doses. In Asians, this medication may show higher blood concentrations, potentially requiring dosage adjustments. For pediatric patients aged 10 to 17, careful use is necessary considering effects on growth and sexual development. This medication contains yellow dye, so caution is advised for individuals allergic to this component. Severe skin reactions may rarely occur, so if a skin rash or allergic symptoms occur, discontinue use immediately and consult a physician. Pregnant or nursing women should not take this medication, and women planning to become pregnant should use appropriate contraceptive methods. In cases of overdose, specific antidotes are not available; hence, treatment should be symptomatic, with liver function and muscle enzyme tests performed as needed. Dizziness may occur during treatment, requiring caution while driving or operating machinery. This medication may impact the liver and muscles; thus, regular check-ups are recommended, and any unusual symptoms should be discussed with healthcare professionals.

Side effects

Allergic reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ophthalmoplegia, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, anorexia, abdominal distension, syncope, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to prevent exposure to air or moisture. It is important to maintain storage temperatures between 1 to 30 degrees Celsius room temperature to preserve its efficacy and safety.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

100 tablets/box [10 tablets/Alu-Alu×10], 30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.